Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 154
interventional 123
Observational 29
Registry 2

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 74
Drug|placebo 24
Device 11
Procedure 3
Behavioral 2
Diagnostic Test 2
Other 2
Behavioral|Other 1
Behavioral|Procedure 1
Device|Drug|Procedure 1
Device|placebo 1
Drug|Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
NA 25
United States 23
France 12
Korea, Republic of 4
Portugal 4
United States|Canada 4
Belgium 3
Japan 3
Russian Federation 3
Belgium|Bulgaria|Germany|Hungary|Netherlands|Spain 2
United States|Bulgaria|Canada|Croatia|Mexico|Poland|Romania|Russian Federation 2
United States|Korea, Republic of|Mexico 2
Australia|Austria|Belgium|Canada|Germany|Netherlands|Poland|Portugal|Spain|United Kingdom| 1
Australia|Austria|Belgium|Finland|France|Germany|Italy|Netherlands|South Africa|Spain|Sweden|Switzerland|United Kingdom 1
Austria|Bosnia and Herzegovina|Croatia|Czechia|France|Germany|Hungary|Italy|Malaysia|Moldova, Republic of|Philippines|Poland|Portugal|Romania|Russian Federation|Serbia|Slovakia|Spain|Taiwan|Ukraine|United Kingdom 1
Austria|Canada|France|Germany|Italy|Lithuania|Spain|United Kingdom| 1
Belgium|Bulgaria|China|Colombia|Czech Republic|Estonia|Finland|France|Germany|Hong Kong|Hungary|India|Ireland|Italy|Korea, Republic of|Latvia|Lithuania|Mexico|Netherlands|Norway|Portugal|Romania|Singapore|Slovakia|Spain|Sweden|Taiwan|Thailand|United Kingdom 1
Belgium|Czech Republic|Finland|France|Germany|Netherlands|Poland|Spain|United Kingdom 1
Costa Rica|El Salvador|Guatemala|Peru 1
Czech Republic|France|United States|Belgium|Brazil|Canada|Germany|Hungary|India|Italy|Mexico|Poland|Romania|Russian Federation|South Africa|United Kingdom 1
Germany 1
Hong Kong|Malaysia|Philippines|Singapore|Taiwan|Thailand 1
Italy|Netherlands|Poland|Russian Federation|Ukraine 1
Netherlands 1
Norway 1
Romania|Mexico|United States|Austria|Bulgaria|Czechia|Denmark|Finland|France|Greece|Italy|Russian Federation|Spain|Switzerland|Turkey 1
Slovakia|Australia|Denmark|France|Germany|Greece|Hungary|India|Italy|Korea, Republic of|Poland|Russian Federation|Serbia|South Africa|Spain|Sweden|Taiwan|United Kingdom 1
Taiwan 1
United Kingdom 1
United States|Argentina|Australia|Belgium|Canada|Chile|Finland|France|Hungary|India|Israel|Korea, Republic of|Mexico|Netherlands|New Zealand|Norway|Poland|Russian Federation|South Africa|Spain|Taiwan|Thailand|Ukraine 1
United States|Argentina|Australia|Bulgaria|Chile|Czechia|Germany|Hungary|Korea, Republic of|Mexico|Poland|Russian Federation|Serbia|Spain|Sweden|Ukraine 1
United States|Argentina|Belgium|Brazil|Canada|Cyprus|France|Germany|Greece|Italy|Poland 1
United States|Argentina|Belgium|Brazil|Canada|Czech Republic|France|Germany|Hungary|Italy|Mexico|Poland|Romania|Russian Federation|United Kingdom 1
United States|Argentina|Bosnia and Herzegovina|Bulgaria|Czechia|Germany|Hong Kong|Hungary|India|Malaysia|Mexico|Poland|Puerto Rico|Romania|Russian Federation|Serbia|Singapore|Thailand 1
United States|Argentina|Brazil|Chile|Germany|India|Korea, Republic of|Puerto Rico|Russian Federation|Ukraine 1
United States|Argentina|Chile|Costa Rica|Korea, Republic of|Puerto Rico|Russian Federation|Ukraine 1
United States|Australia|Bulgaria|Czechia|France|Germany|Hungary|Israel|Korea, Republic of|Poland|Romania|Serbia|Spain|Thailand|Ukraine 1
United States|Belarus|Belgium|Bosnia and Herzegovina|Bulgaria|China|Czechia|France|Germany|Greece|Hungary|India|Israel|Italy|Korea, Republic of|Lebanon|Malaysia|Montenegro|Philippines|Poland|Romania|Russian Federation|Serbia|Singapore|Slovakia|Spain|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Belgium 1
United States|Belgium|Bulgaria|Czechia|France|Greece|Hungary|Israel|Italy|Korea, Republic of|Malaysia|Philippines|Poland|Romania|Serbia|Singapore|Turkey|Ukraine 1
United States|Brazil|Germany|Mexico 1
United States|Bulgaria|Czech Republic|Serbia|Ukraine 1
United States|Bulgaria|Czechia|Hungary|India|Korea, Republic of|Mexico|Poland|Thailand 1
United States|Canada|South Africa 1
United States|Canada|Spain|United Kingdom 1
United States|Germany 1
United States|Germany|Hungary|Lithuania|Poland|Sweden|Switzerland|United Kingdom 1
United States|India|Korea, Republic of|Poland 1

Sites per Study

Site_count Study_Count
1 54
2 7
5 1
7 3
8 3
9 2
10 1
12 2
14 1
15 1
17 1
18 4
22 1
23 1
25 2
26 1
27 1
30 1
31 1
32 1
36 1
37 1
38 1
45 1
46 1
47 1
56 1
57 1
58 1
59 1
60 1
62 1
66 1
73 1
80 1
82 2
84 1
85 1
86 2
88 1
91 1
94 1
102 1
103 2
106 1
109 1
119 1
148 1
151 1
161 1
162 1

Phase

Phase Study_Count
Phase 3 50
Phase 2 24
N/A 20
Phase 4 19
Phase 1 6
Phase 1/Phase 2 2
Early Phase 1 1
Phase 2/Phase 3 1

Number of Arms

Number_of_Arms Count_of_Studies
1 33
2 39
3 10
4 6
5 3
NA 32

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 30 2.00 10.00000 8.00 5.0000 160 17.00 14.0
1st Qu. 30 20.00 14.00000 22.25 55.7500 160 137.50 67.5
Median 30 49.00 16.00000 36.50 84.5000 160 275.00 111.0
Mean 30 94.20 19.33333 36.50 140.2917 160 334.44 200.0
3rd Qu. 30 100.25 19.50000 50.75 180.5000 160 439.00 349.0
Max. 30 500.00 40.00000 65.00 437.0000 160 1345.00 482.0

Trial Group Type

group_type Group_Count
Experimental 115
NA 32
Placebo Comparator 28
Active Comparator 25
Other 7
No Intervention 4
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Parallel Assignment 62
Single Group Assignment 55
Crossover Assignment 4
NA 2

Primary Purpose

primary_purpose Study_Count
Treatment 103
Diagnostic 9
NA 6
Basic Science 3
Other 1
Supportive Care 1

Observational Studies

Studies by Country

Country Study_Count
United States 11
France 6
NA 5
Germany 2
Canada 1
France|Germany|Netherlands|Spain|United Kingdom 1
Germany|Austria 1
United Kingdom 1
United States|Argentina|Australia 1

Sites per Study

Site_count Study_Count
1 23
2 1
11 1
25 1
42 1
62 1
113 1

Enrollment Metrics

Measure Observational
Min 1.0000
1st Qu 72.0000
Median 200.0000
Mean 626.1034
3rd Qu 450.0000
Max 6498.0000

Observation Model

observational_model Study_Count
Cohort 12
NA 8
Case-Control 3
Case-Only 2
Other 2
Case Control 1
Family-Based 1

Time Perspective

time_perspective Study_Count
Prospective 17
NA 6
Cross-Sectional 5
Retrospective 1

Registries

Studies by Country

Country Study_Count
France 1
United States|Australia|Canada 1

Sites per Study

Site_count Study_Count
1 1
30 1

Enrollment Metrics

Measure Registries
Min 500
1st Qu 643
Median 786
Mean 786
3rd Qu 929
Max 1072

Registry Model

observational_model Study_Count
Cohort 2

Time Perspective

time_perspective Study_Count
Prospective 2

Follow-up

target_duration Study_Count
10 Years 1
3 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03283371 Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy https://ClinicalTrials.gov/show/NCT03283371 Active, not recruiting Biogen 2020-01-10
NCT03244345 Depression, Stress and Vulnerability Factors in Drug Resistant Focal Epilepsies https://ClinicalTrials.gov/show/NCT03244345 Recruiting Assistance Publique Hopitaux De Marseille 2020-02-20
NCT03200769 Study of the Efficacy of the Treatment of Sleep Apnea Syndrome by CPAP in Pharmacoresistant Epilepsy https://ClinicalTrials.gov/show/NCT03200769 Recruiting University Hospital, Lille 2021-09-30
NCT03138876 EEG Cap for Identification of Non-Convulsive Status Epilepticus https://ClinicalTrials.gov/show/NCT03138876 Completed Mayo Clinic 2018-08-16
NCT02648529 Brain Maturation in Children With Localization Related Epilepsy https://ClinicalTrials.gov/show/NCT02648529 Completed Hospices Civils de Lyon 2018-12-07
NCT02625090 An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy https://ClinicalTrials.gov/show/NCT02625090 Active, not recruiting UCB Pharma 2021-12-31
NCT02107989 Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database https://ClinicalTrials.gov/show/NCT02107989 Recruiting National Institutes of Health Clinical Center (CC) 2026-03-30
NCT02535091 Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures https://ClinicalTrials.gov/show/NCT02535091 Active, not recruiting SK Life Science, Inc. 2020-12-31
NCT02465970 Effects of Transcranial Direct Current Stimulation (TDCS) in Drug-resistant Partial Epilepsy https://ClinicalTrials.gov/show/NCT02465970 Completed Rennes University Hospital 2018-11-30
NCT02458820 Prompt Diagnosis and Treatment of Subclinical Seizures After Cardiac Arrest https://ClinicalTrials.gov/show/NCT02458820 Completed Children’s Hospital of Philadelphia 2019-01-31
NCT02245061 Cortical Excitability Assessment Using Paired Pulses https://ClinicalTrials.gov/show/NCT02245061 Recruiting Hospices Civils de Lyon 2021-09-30
NCT02220114 Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy https://ClinicalTrials.gov/show/NCT02220114 Completed Orphelia Pharma 2016-12-31
NCT02208492 The Effects on Cognitive Function of Levetiracetam (Keppra®) Compared to Carbamazepine (Tegretol®, Carmazepine®) as Monotherapy for Children With Partial Seizure; A Multicentric Randomized Controlled Study https://ClinicalTrials.gov/show/NCT02208492 Completed Yonsei University 2013-12-31
NCT02076698 Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy https://ClinicalTrials.gov/show/NCT02076698 Active, not recruiting University Hospital, Grenoble 2020-06-30
NCT01311440 Modified Atkins Diet Treatment for Adults With Drug-resistant Epilepsy https://ClinicalTrials.gov/show/NCT01311440 Completed Oslo University Hospital 2017-06-30
NCT01866111 A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures https://ClinicalTrials.gov/show/NCT01866111 Active, not recruiting SK Life Science, Inc. 2015-07-31
NCT01772654 Arterial Spin Labeling MRI Focal Abnormalities in Refractory Epilepsy https://ClinicalTrials.gov/show/NCT01772654 Completed Mayo Clinic 2013-11-30
NCT01749046 Remegal Fixed Dose as Adjunctive Therapy in Patients With Partial Seizures https://ClinicalTrials.gov/show/NCT01749046 Completed Valexfarm 2013-10-31
NCT01745952 Treatment of Difficult to Control Focal Epilepsy With Repetitive Transcranial Magnetic Stimulation (rTMS) https://ClinicalTrials.gov/show/NCT01745952 Completed Universitaire Ziekenhuizen Leuven 2015-05-31
NCT01703143 Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy https://ClinicalTrials.gov/show/NCT01703143 Completed Mayo Clinic 2015-01-31
NCT01527513 Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures https://ClinicalTrials.gov/show/NCT01527513 Completed Bial - Portela C S.A. 2012-03-31
NCT01498822 Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy https://ClinicalTrials.gov/show/NCT01498822 Completed UCB Pharma 2014-07-31
NCT01463306 A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures https://ClinicalTrials.gov/show/NCT01463306 Completed Pfizer 2019-08-22
NCT01397968 Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures https://ClinicalTrials.gov/show/NCT01397968 Active, not recruiting SK Life Science, Inc. 2013-06-30
NCT01389596 A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years https://ClinicalTrials.gov/show/NCT01389596 Completed Pfizer 2016-08-10
NCT04309812 Transcranial Direct Current to Treat Epilepsy at Home https://ClinicalTrials.gov/show/NCT04309812 Enrolling by invitation Stanford University 2021-12-31
NCT03955432 Long-term Cardiac Monitoring in Epilepsy https://ClinicalTrials.gov/show/NCT03955432 Recruiting Northwell Health 2022-03-31
NCT03946618 Neurophysiologically Based Brain State Tracking and Modulation in Focal Epilepsy https://ClinicalTrials.gov/show/NCT03946618 Recruiting Mayo Clinic 2022-04-30
NCT03916848 Novel Network Analysis of Intracranial Stereoelectroencephalography https://ClinicalTrials.gov/show/NCT03916848 Recruiting Great Ormond Street Hospital for Children NHS Foundation Trust 2021-08-31
NCT03882151 Added Value of Automated Electrical Source Localization (EPILOG PreOp®) to Presurgical Evaluation of Refractory Epilepsy https://ClinicalTrials.gov/show/NCT03882151 Recruiting Cliniques universitaires Saint-Luc- Université Catholique de Louvain 2020-06-01
NCT03865771 Sleep Related Memory Consolidation in Children With Age Related Focal Epilepsy. https://ClinicalTrials.gov/show/NCT03865771 Recruiting University Hospital, Strasbourg, France 2020-09-30
NCT03796962 A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy https://ClinicalTrials.gov/show/NCT03796962 Recruiting Xenon Pharmaceuticals Inc. 2020-07-31
NCT03738072 Intracerebral Electrical Stimulation and the Optimisation of Presurgical Planning in Drug-refractory Partial Epilepsy https://ClinicalTrials.gov/show/NCT03738072 Recruiting University Hospital, Toulouse 2021-11-30
NCT03712475 Pharmacokinetics of Two Formulation of Pregabalin https://ClinicalTrials.gov/show/NCT03712475 Completed Yung Shin Pharm. Ind. Co., Ltd. 2018-09-16
NCT03607851 Efficacy and Safety of Rapid Titration Protocols of Lacosamide https://ClinicalTrials.gov/show/NCT03607851 Completed Seoul National University Hospital 2019-06-07
NCT01262677 Once-A-Day Pregabalin For Partial Seizures https://ClinicalTrials.gov/show/NCT01262677 Completed Pfizer 2012-07-31
NCT01235403 Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure https://ClinicalTrials.gov/show/NCT01235403 Completed UCB Pharma 2011-12-31
NCT01190098 Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy https://ClinicalTrials.gov/show/NCT01190098 Completed The Cleveland Clinic 2014-11-30
NCT01140867 Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy https://ClinicalTrials.gov/show/NCT01140867 Completed Eisai Inc. 2010-08-31
NCT01091662 Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic https://ClinicalTrials.gov/show/NCT01091662 Completed Sunovion 2012-11-30
NCT01090934 Localizing the Epileptogenic Zone With High Resolution Electroencephalography https://ClinicalTrials.gov/show/NCT01090934 Completed Central Hospital, Nancy, France 2013-10-31
NCT01048255 Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy https://ClinicalTrials.gov/show/NCT01048255 Completed Vertex Pharmaceuticals Incorporated 2010-11-30
NCT00991757 An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures. https://ClinicalTrials.gov/show/NCT00991757 Completed SK Life Science, Inc. 2010-10-31
NCT00988429 Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures https://ClinicalTrials.gov/show/NCT00988429 Active, not recruiting Bial - Portela C S.A. 2012-01-12
NCT00988156 Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children https://ClinicalTrials.gov/show/NCT00988156 Completed Bial - Portela C S.A. 2012-08-20
NCT00986310 Efficacy of Fluoxetine in Reducing Ictal Hypoventilation in Patients With Partial Epilepsy https://ClinicalTrials.gov/show/NCT00986310 Completed University of California, Davis 2012-02-29
NCT00957684 Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures https://ClinicalTrials.gov/show/NCT00957684 Completed Bial - Portela C S.A. 2005-11-30
NCT00957372 Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy https://ClinicalTrials.gov/show/NCT00957372 Completed Bial - Portela C S.A. 2008-06-30
NCT00957047 Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy https://ClinicalTrials.gov/show/NCT00957047 Completed Bial - Portela C S.A. 2006-08-31
NCT00955357 Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures https://ClinicalTrials.gov/show/NCT00955357 Completed UCB Pharma 2013-04-30
NCT00918047 Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients https://ClinicalTrials.gov/show/NCT00918047 Completed Supernus Pharmaceuticals, Inc. 2010-07-31
NCT00908349 Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy https://ClinicalTrials.gov/show/NCT00908349 Completed Supernus Pharmaceuticals, Inc. 2011-11-30
NCT00900237 Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine https://ClinicalTrials.gov/show/NCT00900237 Completed Bial - Portela C S.A. 2008-12-31
NCT00898560 Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive https://ClinicalTrials.gov/show/NCT00898560 Completed Bial - Portela C S.A. 2008-11-30
NCT00866775 Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs https://ClinicalTrials.gov/show/NCT00866775 Completed Sunovion 2013-05-31
NCT00855738 A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice https://ClinicalTrials.gov/show/NCT00855738 Completed Pfizer 2009-06-30
NCT02495844 A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy https://ClinicalTrials.gov/show/NCT02495844 Completed UCB Pharma 2017-02-28
NCT02804230 MR-Guided Focused Ultrasound in the Treatment of Focal Epilepsy https://ClinicalTrials.gov/show/NCT02804230 Recruiting InSightec 2022-06-30
NCT03446664 Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study https://ClinicalTrials.gov/show/NCT03446664 Recruiting LivaNova 2021-09-30
NCT02491476 Recording “Fast Ripples” Using Microelectrodes During Stereo-encephalography in Patients With Drug-resistant Partial Epilepsy https://ClinicalTrials.gov/show/NCT02491476 Recruiting University Hospital, Toulouse 2022-04-30
NCT00772603 Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures https://ClinicalTrials.gov/show/NCT00772603 Completed Supernus Pharmaceuticals, Inc. 2010-04-30
NCT00744731 An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures https://ClinicalTrials.gov/show/NCT00744731 Completed SK Life Science, Inc. 2010-08-31
NCT00740623 A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures. https://ClinicalTrials.gov/show/NCT00740623 Completed SK Life Science, Inc. 2009-10-31
NCT00655551 Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures https://ClinicalTrials.gov/show/NCT00655551 Completed UCB Pharma 2009-09-30
NCT00655486 Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures https://ClinicalTrials.gov/show/NCT00655486 Completed UCB Pharma 2010-06-30
NCT00643500 Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy https://ClinicalTrials.gov/show/NCT00643500 Completed UCB Pharma 2003-05-31
NCT00643136 A Study of Lyrica as Treatment for Sleep Problems in Patients With Sleep Problems and Seizures https://ClinicalTrials.gov/show/NCT00643136 Completed Pfizer NA
NCT00630357 Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy https://ClinicalTrials.gov/show/NCT00630357 Completed UCB Pharma 2004-07-31
NCT00620555 A Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures https://ClinicalTrials.gov/show/NCT00620555 Completed Pfizer 2010-12-31
NCT00603473 A Phase III Open-Label Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures https://ClinicalTrials.gov/show/NCT00603473 Completed Pfizer 2009-12-31
NCT00552305 To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures https://ClinicalTrials.gov/show/NCT00552305 Completed UCB Pharma 2010-02-28
NCT00537940 Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures https://ClinicalTrials.gov/show/NCT00537940 Completed Pfizer 2013-07-31
NCT00522275 Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures https://ClinicalTrials.gov/show/NCT00522275 Completed UCB Pharma 2009-10-31
NCT00512317 Open-label Extension to Protocol 1042-0600 https://ClinicalTrials.gov/show/NCT00512317 Completed Marinus Pharmaceuticals 2009-12-31
NCT00477295 A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy https://ClinicalTrials.gov/show/NCT00477295 Completed Eisai Inc. 2010-12-31
NCT00465517 A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures https://ClinicalTrials.gov/show/NCT00465517 Completed Marinus Pharmaceuticals 2008-10-31
NCT00448916 Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures https://ClinicalTrials.gov/show/NCT00448916 Completed Pfizer 2013-10-31
NCT00438451 Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs https://ClinicalTrials.gov/show/NCT00438451 Completed Johannes Gutenberg University Mainz 2010-07-31
NCT00437281 Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures https://ClinicalTrials.gov/show/NCT00437281 Completed Pfizer 2012-11-30
NCT00433667 A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures. https://ClinicalTrials.gov/show/NCT00433667 Completed SK Life Science, Inc. 2007-10-31
NCT00425282 A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures. https://ClinicalTrials.gov/show/NCT00425282 Completed SK Life Science, Inc. 2007-10-31
NCT00355082 Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy https://ClinicalTrials.gov/show/NCT00355082 Completed GlaxoSmithKline 2008-11-30
NCT00351611 Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo https://ClinicalTrials.gov/show/NCT00351611 Recruiting Pfizer 2020-11-11
NCT00319501 Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures. https://ClinicalTrials.gov/show/NCT00319501 Completed Pfizer 2014-07-31
NCT00280696 A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset Seizures https://ClinicalTrials.gov/show/NCT00280696 Completed UCB Pharma 2007-11-30
NCT00280059 Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy https://ClinicalTrials.gov/show/NCT00280059 Completed Pfizer 2009-12-31
NCT00275925 Safety and Efficacy of Oxcarbazepine Monotherapy in Adults With Partial Seizures https://ClinicalTrials.gov/show/NCT00275925 Completed Novartis NA
NCT00275912 Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures https://ClinicalTrials.gov/show/NCT00275912 Completed Novartis 2007-09-28
NCT00266604 A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy https://ClinicalTrials.gov/show/NCT00266604 Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. NA
NCT00245713 Determine Effects of Adjunctive Levetiracetam on Sleep Architecture in Adults With Partial Onset Epilepsy. https://ClinicalTrials.gov/show/NCT00245713 Completed UCB Pharma 2004-11-30
NCT00236886 Prospective Pilot Study on Metabolism and Weight Changes in Topiramate-Treated Epilepsy Patients https://ClinicalTrials.gov/show/NCT00236886 Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. NA
NCT00236873 A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures. https://ClinicalTrials.gov/show/NCT00236873 Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. NA
NCT00236860 A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures https://ClinicalTrials.gov/show/NCT00236860 Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. NA
NCT00236847 A Study of the Efficacy and Safety of Topiramate in the Treatment of Patients With Epilepsy. https://ClinicalTrials.gov/show/NCT00236847 Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. NA
NCT00236743 A Study of the Effectiveness and Safety of Topiramate in the Treatment of Children With Epilepsy https://ClinicalTrials.gov/show/NCT00236743 Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. NA
NCT00236730 A Study of the Efficacy and Safety of Topiramate in the Treatment of Patients With Difficult to Control Epilepsy https://ClinicalTrials.gov/show/NCT00236730 Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. NA
NCT00236691 A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures. https://ClinicalTrials.gov/show/NCT00236691 Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. NA
NCT00231556 A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy https://ClinicalTrials.gov/show/NCT00231556 Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. NA
NCT00230698 A Study of the Effectiveness and Safety of Topiramate Monotherapy in Patients With Recently Diagnosed Partial-Onset Seizure https://ClinicalTrials.gov/show/NCT00230698 Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. NA
NCT00212745 Pilot Trial of a Behavioral Treatment for Epilepsy https://ClinicalTrials.gov/show/NCT00212745 Completed Oregon Health and Science University 2009-03-31
NCT00210652 An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With Epilepsy https://ClinicalTrials.gov/show/NCT00210652 Completed SK Life Science, Inc. 2010-03-31
NCT00210522 An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy https://ClinicalTrials.gov/show/NCT00210522 Completed SK Life Science, Inc. 2010-06-30
NCT00175929 A Study of Brivaracetam in Subjects With Partial Onset Seizures https://ClinicalTrials.gov/show/NCT00175929 Completed UCB Pharma 2006-03-31
NCT00175890 A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures. https://ClinicalTrials.gov/show/NCT00175890 Completed UCB Pharma 2007-01-31
NCT00160654 Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy https://ClinicalTrials.gov/show/NCT00160654 Completed UCB Pharma 2006-05-31
NCT00160628 Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy https://ClinicalTrials.gov/show/NCT00160628 Completed UCB Pharma 2004-10-31
NCT00160615 Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method https://ClinicalTrials.gov/show/NCT00160615 Completed UCB Pharma 2007-01-17
NCT00152516 Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures https://ClinicalTrials.gov/show/NCT00152516 Completed UCB Pharma 2008-06-30
NCT00152503 Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam https://ClinicalTrials.gov/show/NCT00152503 Completed UCB Pharma 2007-01-31
NCT00152451 Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures https://ClinicalTrials.gov/show/NCT00152451 Completed UCB Pharma 2007-01-31
NCT00152373 Double-blind, Placebo-controlled Study of Levetiracetam in Adults With POS https://ClinicalTrials.gov/show/NCT00152373 Completed UCB Pharma 2005-05-31
NCT00151879 Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures https://ClinicalTrials.gov/show/NCT00151879 Completed UCB Pharma 2006-05-31
NCT00150709 A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy https://ClinicalTrials.gov/show/NCT00150709 Completed UCB Pharma 2006-01-31
NCT00150293 Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures. https://ClinicalTrials.gov/show/NCT00150293 Completed Pfizer NA
NCT00143143 Pregabalin Open-Label Extension Trial in Patients With Partial Seizures https://ClinicalTrials.gov/show/NCT00143143 Completed Pfizer NA
NCT00141414 To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy. https://ClinicalTrials.gov/show/NCT00141414 Completed Pfizer NA
NCT00141388 To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures https://ClinicalTrials.gov/show/NCT00141388 Completed Pfizer NA
NCT00141336 To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures. https://ClinicalTrials.gov/show/NCT00141336 Completed Pfizer NA
NCT00141245 To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures. https://ClinicalTrials.gov/show/NCT00141245 Completed Pfizer NA
NCT00113815 Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures https://ClinicalTrials.gov/show/NCT00113815 Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2007-06-30
NCT00113165 Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures https://ClinicalTrials.gov/show/NCT00113165 Completed GlaxoSmithKline 2007-07-31
NCT00105040 A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures https://ClinicalTrials.gov/show/NCT00105040 Completed UCB Pharma 2007-03-31
NCT00050934 Pediatric Epilepsy Study https://ClinicalTrials.gov/show/NCT00050934 Completed Novartis 2004-06-30

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03321240 Study of Predictive Biomarkers for Rational Management of Drug-resistant Epilepsy Associated With Focal Cortical Dysplasia https://ClinicalTrials.gov/show/NCT03321240 Recruiting University Hospital, Strasbourg, France 2022-12-15
NCT03278210 National Study on the Interest of EEG-fMRI in the Presurgical Evaluation of Partial Epilepsies Drug https://ClinicalTrials.gov/show/NCT03278210 Recruiting University Hospital, Lille 2020-04-30
NCT03082222 ZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions https://ClinicalTrials.gov/show/NCT03082222 Completed Eisai Inc. 2018-10-29
NCT02898935 Improvement of the Accuracy of Spatial Representation of Invasive Exploratory Electrodes in Focal Epilepsy https://ClinicalTrials.gov/show/NCT02898935 Completed Fondation Ophtalmologique Adolphe de Rothschild 2018-05-31
NCT01858285 Genetics of Severe Early Onset Epilepsies https://ClinicalTrials.gov/show/NCT01858285 Recruiting Boston Children’s Hospital 2030-12-31
NCT01273129 Surgery as a Treatment for Medically Intractable Epilepsy https://ClinicalTrials.gov/show/NCT01273129 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT01673282 Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy https://ClinicalTrials.gov/show/NCT01673282 Completed UCB Pharma 2015-07-31
NCT01663545 Brain P-gp and Inflammation in People With Epilepsy https://ClinicalTrials.gov/show/NCT01663545 Completed National Institutes of Health Clinical Center (CC) NA
NCT01587339 Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy https://ClinicalTrials.gov/show/NCT01587339 Completed GlaxoSmithKline 2011-03-31
NCT01457989 Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304 https://ClinicalTrials.gov/show/NCT01457989 Completed GlaxoSmithKline 2011-08-31
NCT01441401 Safety and Efficacy of Gabapen for Pediatric (Regulatory Post Marketing Commitment Plan) https://ClinicalTrials.gov/show/NCT01441401 Completed Pfizer 2014-08-31
NCT01373190 Thermographic Examination of Skin Temperatures in Individuals With Focal Onset Epilepsy https://ClinicalTrials.gov/show/NCT01373190 Completed Atlantic University 2012-04-30
NCT01332539 An Observational Study to Assess the Burden of Drug-resistant Partial Epilepsy in Italy https://ClinicalTrials.gov/show/NCT01332539 Completed GlaxoSmithKline 2012-11-30
NCT03268824 Impact of Epileptic Discharge on the Structural Connectivity of the Developing Brain https://ClinicalTrials.gov/show/NCT03268824 Recruiting Fondation Ophtalmologique Adolphe de Rothschild 2021-06-30
NCT04061707 Subcutaneous EEG: Forecasting of Epileptic Seizures https://ClinicalTrials.gov/show/NCT04061707 Recruiting King’s College London 2021-05-15
NCT02890641 Genetic and Electrophysiologic Study in Focal Drug-resistant Epilepsies https://ClinicalTrials.gov/show/NCT02890641 Recruiting Fondation Ophtalmologique Adolphe de Rothschild 2030-12-31
NCT03644732 Atlas of Human Cognition by SEEG (MAPCOG-SEEG) https://ClinicalTrials.gov/show/NCT03644732 Recruiting University Hospital, Grenoble 2028-03-31
NCT03478852 Investigating Epilepsy: Screening, Evaluation and Treatment https://ClinicalTrials.gov/show/NCT03478852 Recruiting National Institutes of Health Clinical Center (CC) 2027-07-30
NCT01098162 Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug https://ClinicalTrials.gov/show/NCT01098162 Completed UCB Pharma 2013-07-31
NCT00894478 Improving Lesion Detection in Children With Magnetic Resonance Imaging (MRI)-Negative Partial Epilepsy Using Diffusion Tensor Imaging https://ClinicalTrials.gov/show/NCT00894478 Completed The Hospital for Sick Children 2012-05-31
NCT00771927 Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures https://ClinicalTrials.gov/show/NCT00771927 Completed UCB Pharma 2012-03-31
NCT00706160 Language Mapping in Patients With Epilepsy https://ClinicalTrials.gov/show/NCT00706160 Completed National Institutes of Health Clinical Center (CC) NA
NCT00567268 Drug Use Investigation Of Gabapentin https://ClinicalTrials.gov/show/NCT00567268 Completed Pfizer 2014-05-31
NCT00552045 Epilepsy Phenome/Genome Project https://ClinicalTrials.gov/show/NCT00552045 Completed University of California, San Francisco 2013-12-31
NCT00072813 MRI in Autosomal Dominant Partial Epilepsy With Auditory Features https://ClinicalTrials.gov/show/NCT00072813 Completed National Institutes of Health Clinical Center (CC) 2009-11-12
NCT00071305 Non-Invasive Seizure Localization in Patients With Medically Refractory Localization Related Epilepsy: Synchronized MEG-EEG Recordings https://ClinicalTrials.gov/show/NCT00071305 Completed National Institutes of Health Clinical Center (CC) 2009-10-06
NCT00001666 Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy https://ClinicalTrials.gov/show/NCT00001666 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001932 Serotonin Receptors in Seizure Disorders https://ClinicalTrials.gov/show/NCT00001932 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001325 Metabolic Abnormalities in Children With Epilepsy https://ClinicalTrials.gov/show/NCT00001325 Completed National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02572297 National Network for the Study of Predictors and Prevention of Sudden Unexpected Death in Drug-resistant Partial Epilepsies https://ClinicalTrials.gov/show/NCT02572297 Completed Hospices Civils de Lyon 2015-02-28
NCT02126774 The Human Epilepsy Project https://ClinicalTrials.gov/show/NCT02126774 Active, not recruiting NYU Langone Health 2020-06-01